Quinagolide - a valuable treatment option for hyperprolactinaemia -- Barlier and Jaquet 154 (2): 187 -- European Journal of Endocrinology
CAB doesn't seem to be getting the PRL level down as much as we'd like, even at 0.75mg x 4/week. We're considering switching to QUI (Quinagolide). QUI appears to offer similar effectiveness in most studies. In addition, it's not an ergot-derived drug, so it should not have some of the risks that Bromocriptine and CAB have.
Subscribe to:
Posts (Atom)
Posts
